诺和诺德掷23亿欧元落子意大利阿纳尼——“战略利益”地位加持,欧洲减肥药供应链版图重构

药时代
12 Jul

新型ADC层出,临床运营如何应对?| 药时代直播间正文共:1602字1图预计阅读时间:4分钟药时代报道:全球GLP-1赛道再掀巨浪。诺和诺德公司近日正式宣布,将在2025—2029年间投资23亿欧元,于意大利中部拉齐奥大区阿纳尼(Anagni)新建一座高活性制剂生产基地,专门用于减重与糖尿病药物的生产。项目已获意大利政府授予“国家利益战略地位”(Strategic National ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10